Literature DB >> 20372087

Towards new tuberculosis vaccines.

Stefan Svenson1, Gunilla Källenius, Andrzej Pawlowski, Beston Hamasur.   

Abstract

According to WHO, about one third of the world's population is infected with bacteria of the Mycobacterium tuberculosis complex. Currently there is globally 9.15 million recorded cases of overt tuberculosis (TB) annually and due to lack of adequate diagnostics presumably a large but unknown number of non-recorded cases. TB is estimated to cause 1.65 million deaths per annum which accounts for one-fifth of all deaths by infectious diseases of adults in low-income countries. During recent years a rapid spread of multi-drug resistant bacteria causing about 0.5 million TB cases per year has worsened the problem. The live attenuated Bacillus Calmette-Guérin (BCG) vaccine which is the only currently available TB vaccine does not confer any significant protection against the most common and contagious form of TB-adult pulmonary TB.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372087     DOI: 10.4161/hv.6.4.10711

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  12 in total

1.  OX40 ligand fusion protein delivered simultaneously with the BCG vaccine provides superior protection against murine Mycobacterium tuberculosis infection.

Authors:  Robert J Snelgrove; Megan M Cornere; Lorna Edwards; Belinda Dagg; James Keeble; Angela Rodgers; Daphne E Lyonga; Graham R Stewart; Douglas B Young; Barry Walker; Tracy Hussell
Journal:  J Infect Dis       Date:  2012-02-07       Impact factor: 5.226

2.  Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis.

Authors:  Carlos R Zárate-Bladés; Rodrigo F Rodrigues; Patricia R M Souza; Wendy M Rios; Luana S Soares; Rogério S Rosada; Izaíra T Brandão; Ana Paula Masson; Elaine M Floriano; Simone G Ramos; Celio L Silva
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

3.  Aptamer against mannose-capped lipoarabinomannan inhibits virulent Mycobacterium tuberculosis infection in mice and rhesus monkeys.

Authors:  Qin Pan; Qilong Wang; Xiaoming Sun; Xianru Xia; Shimin Wu; Fengling Luo; Xiao-Lian Zhang
Journal:  Mol Ther       Date:  2014-02-27       Impact factor: 11.454

4.  Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.

Authors:  Ranadhir Dey; Pradeep K Dagur; Angamuthu Selvapandiyan; J Philip McCoy; Poonam Salotra; Robert Duncan; Hira L Nakhasi
Journal:  J Immunol       Date:  2013-01-21       Impact factor: 5.422

Review 5.  Prime-boost approaches to tuberculosis vaccine development.

Authors:  Neha Dalmia; Alistair J Ramsay
Journal:  Expert Rev Vaccines       Date:  2012-10       Impact factor: 5.217

Review 6.  Current status of new tuberculosis vaccine in children.

Authors:  Yu Pang; Aihua Zhao; Chad Cohen; Wanli Kang; Jie Lu; Guozhi Wang; Yanlin Zhao; Suhua Zheng
Journal:  Hum Vaccin Immunother       Date:  2016-03-22       Impact factor: 3.452

7.  Comparative tuberculosis (TB) prevention effectiveness in children of Bacillus Calmette-Guérin (BCG) vaccines from different sources, Kazakhstan.

Authors:  Michael Favorov; Mohammad Ali; Aigul Tursunbayeva; Indira Aitmagambetova; Paul Kilgore; Shakhimurat Ismailov; Terence Chorba
Journal:  PLoS One       Date:  2012-03-09       Impact factor: 3.240

8.  Polyantigenic interferon-γ responses are associated with protection from TB among HIV-infected adults with childhood BCG immunization.

Authors:  Timothy Lahey; Brian K Mitchell; Robert D Arbeit; Siddharth Sheth; Mecky Matee; C Robert Horsburgh; Todd MacKenzie; Lillian Mtei; Muhammad Bakari; Jenni M Vuola; Kisali Pallangyo; C Fordham von Reyn
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

9.  New therapeutic approach for latent tuberculosis infection.

Authors:  Sandeep Kumar Gupta
Journal:  Lung India       Date:  2011-07

10.  Wild-type phosphoribosylpyrophosphate synthase (PRS) from Mycobacterium tuberculosis: a bacterial class II PRS?

Authors:  Ardala Breda; Leonardo K B Martinelli; Cristiano V Bizarro; Leonardo A Rosado; Caroline B Borges; Diógenes S Santos; Luiz A Basso
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.